FAIRFIELD, N.J., Feb. 1,
2012 /PRNewswire/ -- Aperture Health, Inc. (OTC: APRE) announced
that it has entered into planning discussions with small and large
animal veterinarians and other industry professionals, with a
specific focus on the equine show and racing disciplines. The
Pet Med industry in the United
States is in excess of $4B. Aperture's CEO, James Hennig, R.Ph. became certified in
veterinary compounding to be able to move the company into the fast
growing pet med arena. Triad has historically been a provider of
infusion therapies to major vet hospitals in the metro NJ area.
James Hennig, R.Ph, Chief
Executive Officer and Chairman of the Board of Directors commented,
"We are very excited at the prospects of forming partnerships and
alliances with noted large and small animal Veterinarians and in
particular other equine sport professionals who require our
capabilities to provide complex compounding and IV services.
The rapid growth in this industry and the high margins
attributable to penetrating this relatively untapped market will
provide Aperture and Triad tremendous opportunity to increase and
accelerate revenue and bottom line growth."
About Aperture Health, and Triad Therapeutics
Aperture Health through its wholly owned subsidiary Triad
Therapeutics operates a fully JCAHO accredited home IV therapy
company, achieving this "gold standard" status in 2007. The company
has built a well respected reputation in its industry for its
therapy expertise and commitment to care for its patient clients.
The company services clients throughout the States of New Jersey, New
York and Connecticut,
providing opportunity for organic growth. Triad's full time
marketing and sales personnel continuously represent the company in
the core services areas, growing and maintaining the company's
referral source base. Patient referrals are made from physicians,
hospitals, insurance companies, veterinarians and hospice care
providers that have established a professional rapport with
Triad.
Safe Harbor
Certain statements in this news release are
forward-looking, including (without limitation) growing revenues
and earnings, expected results from current projects and attracting
new business. Undue reliance should not be placed on such
forward-looking statements because the matters they describe are
subject to known and unknown risks, uncertainties and other
unpredictable factors, many of which are beyond the Company's
control. The Company's actual results, performance and trends could
differ materially from those indicated or implied by such
statements as a result of various factors, including (without
limitation) the continued strengthening of Triad's selling and
marketing functions, continued customer satisfaction, contract
renewal, new product development, continued availability of capable
dedicated personnel, continued cost management, success and
availability of acquisitions, availability of financing and other
factors, as well as by factors applicable to most companies such as
general economic, competitive and other business and civil
conditions. Information regarding certain of those and other
risk factors and cautionary statements that could affect future
results, performance or trends is discussed in the Company's OTC
Disclosure Statement and unaudited management financials posted on
www.pinksheets.com . All of the Company's forward-looking
statements are expressly qualified by all such risk factors and
other cautionary statements. The information set forth herein
speaks only as of the date hereof.
SOURCE Aperture Health, Inc.